PL4574996T3 - Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów - Google Patents

Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów

Info

Publication number
PL4574996T3
PL4574996T3 PL25155747.6T PL25155747T PL4574996T3 PL 4574996 T3 PL4574996 T3 PL 4574996T3 PL 25155747 T PL25155747 T PL 25155747T PL 4574996 T3 PL4574996 T3 PL 4574996T3
Authority
PL
Poland
Prior art keywords
systems
detection
treatment
methods
test results
Prior art date
Application number
PL25155747.6T
Other languages
English (en)
Inventor
Helmy Eltoukhy
AmirAli TALASAZ
Bahram Ghaffarzadeh Kermani
Nnamdi IHUEGBU
Original Assignee
Guardant Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4574996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guardant Health, Inc. filed Critical Guardant Health, Inc.
Publication of PL4574996T3 publication Critical patent/PL4574996T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL25155747.6T 2014-12-31 2015-12-28 Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów PL4574996T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098426P 2014-12-31 2014-12-31
US201562155763P 2015-05-01 2015-05-01

Publications (1)

Publication Number Publication Date
PL4574996T3 true PL4574996T3 (pl) 2026-03-02

Family

ID=56284976

Family Applications (1)

Application Number Title Priority Date Filing Date
PL25155747.6T PL4574996T3 (pl) 2014-12-31 2015-12-28 Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów

Country Status (9)

Country Link
US (5) US20170260590A1 (pl)
EP (5) EP3766986B1 (pl)
JP (4) JP6783768B2 (pl)
CN (2) CN107406876B (pl)
AU (3) AU2015374259B2 (pl)
ES (4) ES3059886T3 (pl)
GB (1) GB2552267B (pl)
PL (1) PL4574996T3 (pl)
WO (1) WO2016109452A1 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
CN111254500B (zh) 2012-12-10 2024-01-23 分析生物科学有限公司 靶向基因组分析的方法
TWI813141B (zh) 2014-07-18 2023-08-21 香港中文大學 Dna混合物中之組織甲基化模式分析
US20160053301A1 (en) 2014-08-22 2016-02-25 Clearfork Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
EP3766986B1 (en) * 2014-12-31 2022-06-01 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
HUE058263T2 (hu) 2015-02-10 2022-07-28 Univ Hong Kong Chinese Mutációk detektálása rákszûrési és magzatelemzési célból
IL305462A (en) 2015-07-23 2023-10-01 Univ Hong Kong Chinese DNA fragmentation pattern analysis suitable clean
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
JP6991134B2 (ja) 2015-10-09 2022-01-12 ガーダント ヘルス, インコーポレイテッド 無細胞dnaを使用する集団ベースの処置レコメンダ
JP6913089B2 (ja) 2015-11-11 2021-08-04 レゾリューション バイオサイエンス, インコーポレイテッド Dnaライブラリーの高効率構築
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
US11319594B2 (en) 2016-08-25 2022-05-03 Resolution Bioscience, Inc. Methods for the detection of genomic copy changes in DNA samples
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3461274B1 (en) 2016-09-30 2020-11-04 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
KR20260032575A (ko) 2016-11-30 2026-03-09 더 차이니즈 유니버시티 오브 홍콩 소변 및 기타 샘플에서의 무세포 dna의 분석
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
SG11201906397UA (en) 2017-01-25 2019-08-27 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
KR102083501B1 (ko) * 2017-02-09 2020-03-02 사회복지법인 삼성생명공익재단 종양 치료를 위한 표적 유전자 판별 방법
US10535434B2 (en) * 2017-04-28 2020-01-14 4D Path Inc. Apparatus, systems, and methods for rapid cancer detection
CN110914450B (zh) * 2017-05-16 2024-07-02 夸登特健康公司 无细胞dna的体细胞来源或种系来源的鉴定
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CN111051536A (zh) 2017-07-26 2020-04-21 香港中文大学 利用不含细胞的病毒核酸改善癌症筛选
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
JP7072825B2 (ja) * 2017-09-13 2022-05-23 三菱電機ソフトウエア株式会社 コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法
CA3075932A1 (en) * 2017-09-20 2019-03-28 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
JP2021503922A (ja) * 2017-11-28 2021-02-15 グレイル, インコーポレイテッドGrail, Inc. ターゲットシーケンシングのためのモデル
WO2019108807A1 (en) * 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
WO2019109086A1 (en) 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
JP2021513342A (ja) * 2018-02-12 2021-05-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 腫瘍の遺伝的不均一性を評価することによって治療法に対する応答を予測する方法
KR102933367B1 (ko) * 2018-02-27 2026-03-03 코넬 유니버시티 게놈-와이드 통합을 통한 순환 종양 dna의 초민감 검출
WO2019169044A1 (en) * 2018-02-27 2019-09-06 Cornell University Systems and methods for detection of residual disease
DE202019005627U1 (de) 2018-04-02 2021-05-31 Grail, Inc. Methylierungsmarker und gezielte Methylierungssondenpanels
WO2019195769A1 (en) * 2018-04-06 2019-10-10 The Brigham And Women's Hospital, Inc. Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas
WO2019204360A1 (en) * 2018-04-16 2019-10-24 Grail, Inc. Systems and methods for determining tumor fraction in cell-free nucleic acid
US20240254547A1 (en) * 2018-04-27 2024-08-01 Kao Corporation Highly accurate sequencing method
WO2019215223A1 (en) * 2018-05-08 2019-11-14 F. Hoffmann-La Roche Ag Method of cancer prognosis by assessing tumor variant diversity by means of establishing diversity indices
WO2020023420A2 (en) * 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020069350A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
GB2577548B (en) * 2018-09-28 2022-10-26 Siemens Healthcare Gmbh Method for determining a subject's genetic copy number value
JP7499239B2 (ja) * 2018-11-13 2024-06-13 ミリアド・ジェネティックス・インコーポレイテッド 体細胞変異のための方法およびシステム、ならびにそれらの使用
CN121575489A (zh) * 2018-11-21 2026-02-27 卡里乌斯公司 感染性疾病的检测和预测
CN109712671B (zh) * 2018-12-20 2020-06-26 北京优迅医学检验实验室有限公司 基于ctDNA的基因检测装置、存储介质及计算机系统
US12362038B2 (en) * 2019-01-10 2025-07-15 Travera, Inc. Identifying cancer therapies
WO2020160414A1 (en) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
WO2020249704A1 (en) * 2019-06-13 2020-12-17 F. Hoffmann-La Roche Ag Systems and methods with improved user interface for interpreting and visualizing longitudinal data
CN110428905B (zh) * 2019-07-02 2022-03-29 江南大学附属医院 一种肿瘤生长趋势预测方法
US20220259667A1 (en) * 2019-07-22 2022-08-18 Roche Sequencing Solutions, Inc. Systems and methods for cell of origin determination from variant calling data
AU2020345621A1 (en) * 2019-09-09 2022-04-07 University Of Utah Research Foundation Targeted sequencing to detect and quantify low levels of methylated DNA
EP3809414A1 (en) * 2019-10-15 2021-04-21 Koninklijke Philips N.V. Method and apparatus for assessing patient's response to therapy
CN110895963A (zh) * 2019-10-31 2020-03-20 深圳兰丁医学检验实验室 一种基于人工智能的细胞dna定量检测系统
EP4103748A4 (en) 2020-02-14 2024-03-13 The Johns Hopkins University METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
CA3180386A1 (en) * 2020-05-29 2021-12-02 Yi-Wen Chen Genetic diagnostic tool for facioscapulohumeral muscular dystrophy (fshd)
IL300826A (en) 2020-08-25 2023-04-01 Seer Inc Compositions and methods for testing proteins and nucleic acids
IL303423A (en) * 2020-12-07 2023-08-01 Hoffmann La Roche Techniques for generating predictive results related to oncology treatment lines using artificial intelligence
CN117063239A (zh) * 2021-03-05 2023-11-14 夸登特健康公司 用于分析分子响应的方法和相关方面
US12423593B2 (en) * 2021-06-11 2025-09-23 Massachusetts Institute Of Technology Systems and methods for synthetic interventions
US12548645B2 (en) * 2021-07-30 2026-02-10 Guardant Health, Inc. Computer architecture for identifying lines of therapy
CN114267445B (zh) * 2021-12-23 2024-09-06 众阳健康科技集团有限公司 一种诊断一致性检验方法、系统、设备及介质
WO2023157850A1 (ja) 2022-02-18 2023-08-24 Dic株式会社 硫化オレフィンの製造方法
WO2023183750A1 (en) * 2022-03-23 2023-09-28 Foundation Medicine, Inc. Methods and systems for determining tumor heterogeneity
CN118581200A (zh) * 2023-03-01 2024-09-03 体学生物科技股份有限公司 核酸分子的检测方法、检测套组及检测卡匣
CN116403644B (zh) * 2023-03-03 2023-12-05 深圳吉因加信息科技有限公司 一种用于癌症风险预测的方法及装置
US20240339215A1 (en) * 2023-04-06 2024-10-10 Board Of Regents, The University Of Texas System System and method for drug selection
US20240363198A1 (en) * 2023-04-27 2024-10-31 Cardiai Technologies System for identifying genetic variants and method thereof
CN117219162B (zh) * 2023-09-12 2024-07-02 四川大学 针对肿瘤组织str图谱进行身源鉴定的证据强度评估方法
USD1118634S1 (en) * 2023-10-11 2026-03-17 Open Text Inc. Display screen or portion thereof with graphical user interface for visualizing connections between base entities of a story corresponding to a security issue

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7385605B2 (en) * 2003-12-04 2008-06-10 International Business Machines Corporation Computer display system for dynamically modifying stacked area line graphs to change the order or presence of a set of stacked areas in the graph respectively representative of the proportions contributed to a total by each of a set of time dependent variables
US20060199189A1 (en) * 2005-03-07 2006-09-07 Bradford Sherry A Low-dose, sequenced, individualized chemotherapy dosing method
NZ597655A (en) * 2009-07-08 2013-05-31 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
NO2729579T3 (pl) 2011-07-08 2018-03-03
AU2011373694A1 (en) * 2011-07-26 2013-05-02 Verinata Health, Inc. Method for determining the presence or absence of different aneuploidies in a sample
WO2013040583A2 (en) * 2011-09-16 2013-03-21 Complete Genomics, Inc Determining variants in a genome of a heterogeneous sample
SG190466A1 (en) * 2011-11-18 2013-06-28 Agency Science Tech & Res Methods for diagnosis and/or prognosis of ovarian cancer
PT2828218T (pt) 2012-03-20 2020-11-11 Univ Washington Through Its Center For Commercialization Métodos para baixar a taxa de erro da sequenciação paralela massiva de adn utilizando sequenciação duplex de consensus
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
CN104781421B (zh) * 2012-09-04 2020-06-05 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
SI4056712T1 (sl) * 2012-09-20 2024-10-30 The Chinese University Of Hong Kong Neinvazivno določanje metiloma tumorja iz plazme
US20140287937A1 (en) 2013-02-21 2014-09-25 Toma Biosciences, Inc. Methods for assessing cancer
CN114574581A (zh) 2013-03-15 2022-06-03 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
WO2014151117A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
US10435740B2 (en) 2013-04-01 2019-10-08 University Of Florida Research Foundation, Incorporated Determination of methylation state and chromatin structure of target genetic loci
EP3003377A1 (en) * 2013-05-31 2016-04-13 Novartis AG Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
CA2958801A1 (en) * 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP3766986B1 (en) * 2014-12-31 2022-06-01 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
JP6991134B2 (ja) * 2015-10-09 2022-01-12 ガーダント ヘルス, インコーポレイテッド 無細胞dnaを使用する集団ベースの処置レコメンダ
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
US11384382B2 (en) * 2016-04-14 2022-07-12 Guardant Health, Inc. Methods of attaching adapters to sample nucleic acids
USD810111S1 (en) * 2016-09-08 2018-02-13 Sap Se Electronic display screen with a graphical user interface
EP3785269A4 (en) 2018-03-29 2021-12-29 Freenome Holdings, Inc. Methods and systems for analyzing microbiota
USD1013704S1 (en) * 2021-07-09 2024-02-06 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
US20240052419A1 (en) * 2022-08-10 2024-02-15 Guardant Health, Inc. Methods and systems for detecting genetic variants
US20240071628A1 (en) * 2022-08-24 2024-02-29 Guardant Health, Inc. Database for therapeutic interventions

Also Published As

Publication number Publication date
EP4123032A1 (en) 2023-01-25
WO2016109452A1 (en) 2016-07-07
EP3766986A1 (en) 2021-01-20
EP3240911A1 (en) 2017-11-08
ES3017068T3 (en) 2025-05-12
GB201712299D0 (en) 2017-09-13
ES3059886T3 (en) 2026-03-24
JP6783768B2 (ja) 2020-11-11
US20220213562A1 (en) 2022-07-07
EP3240911B1 (en) 2020-08-26
EP4123032C0 (en) 2025-02-05
JP7145907B2 (ja) 2022-10-03
CN107406876B (zh) 2021-09-07
EP4123032B1 (en) 2025-02-05
JP7458360B2 (ja) 2024-03-29
AU2020264326B2 (en) 2023-05-18
AU2023206196A1 (en) 2023-08-10
US20240141432A9 (en) 2024-05-02
EP3240911A4 (en) 2018-11-21
AU2020264326A1 (en) 2020-11-26
JP2020127408A (ja) 2020-08-27
JP2018507682A (ja) 2018-03-22
US20210040565A1 (en) 2021-02-11
AU2015374259A1 (en) 2017-08-10
EP4574996A2 (en) 2025-06-25
JP2022024040A (ja) 2022-02-08
EP4715065A3 (en) 2026-04-29
EP3766986B1 (en) 2022-06-01
ES2828279T3 (es) 2021-05-25
EP4574996B1 (en) 2025-11-05
USD1077824S1 (en) 2025-06-03
EP4574996C0 (en) 2025-11-05
EP4574996A3 (en) 2025-07-16
CN113930507A (zh) 2022-01-14
US20170260590A1 (en) 2017-09-14
JP2024029174A (ja) 2024-03-05
EP4715065A2 (en) 2026-03-25
US20210395837A1 (en) 2021-12-23
GB2552267A (en) 2018-01-17
ES2923602T3 (es) 2022-09-28
GB2552267B (en) 2020-06-10
CN107406876A (zh) 2017-11-28
AU2015374259B2 (en) 2020-08-13
CA2972433A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
PL4574996T3 (pl) Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów
IL281566A (en) Methods and systems for diagnosing and treating health ailments
IL272433A (en) Systems and methods for analysis of tissue images
IL290994A (en) Methods of diagnosing and treating conduct disorder
PL3798444T3 (pl) System i sposób detekcji ptaków
EP3001196B8 (en) Blood testing system and method
IL250521A0 (en) Method of malware detection and system thereof
EP3182886A4 (en) System and method for noninvasive analysis of tissue
DK3182901T3 (da) System og fremgangsmåde til ikke-invasiv analyse af kropsfluider
PL3171765T3 (pl) Zbieranie i analiza danych do celów diagnostycznych
IL232853A (en) Method and system for image georegistration
EP3229668A4 (en) Device, system and methods for assessing tissue structures, pathology, and healing
PL3242126T3 (pl) Sposób i system obrazowania promieniowaniem podwójnej energii
DK3202305T3 (da) Engangsendoskop og system
DK3220973T3 (da) Kunstigt lungesystem og fremgangsmåder til anvendelse deraf
SG11201703202YA (en) Method and system for detection of disease agents in blood
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
IL251121A0 (en) Methods and systems for diagnostic mapping of bladder
BR112017010355A2 (pt) sistema de monitoramento de paciente, e, método
IL246658B (en) Systems and methods for diagnosing sleep
SG11201605105UA (en) Disease detection system and disease detection method
IL252224B (en) Systems and methods for performing electrocardiograms
IL251440B (en) Methods and systems for identifying analytes
FR3019217B1 (fr) Procede et systeme de reactivation rapide de turbomachine
DK3177920T3 (da) På-stedet-diagnosesystem og fremgangsmåde dertil